[
  {
    "ts": null,
    "headline": "Kenox Pharmaceuticals Appoints Dr. Julianne Berry as Vice President of R&D and Manufacturing",
    "summary": "Kenox Pharmaceuticals Inc. has announced the appointment of Dr. Julianne Berry as Vice President of R&D and Manufacturing. In her new role, Dr. Berry will oversee Kenox's integrated development, manufacturing, and testing operations, driving innovation and efficiency across the company's expanding portfolio of inhaled, nasal, and ophthalmic drug–device combination products.",
    "url": "https://finnhub.io/api/news?id=52053e66d63a9eee51b3d46478e74e127818917595cde3cbaff5d4c02ab241bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761073860,
      "headline": "Kenox Pharmaceuticals Appoints Dr. Julianne Berry as Vice President of R&D and Manufacturing",
      "id": 137187978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Kenox Pharmaceuticals Inc. has announced the appointment of Dr. Julianne Berry as Vice President of R&D and Manufacturing. In her new role, Dr. Berry will oversee Kenox's integrated development, manufacturing, and testing operations, driving innovation and efficiency across the company's expanding portfolio of inhaled, nasal, and ophthalmic drug–device combination products.",
      "url": "https://finnhub.io/api/news?id=52053e66d63a9eee51b3d46478e74e127818917595cde3cbaff5d4c02ab241bd"
    }
  },
  {
    "ts": null,
    "headline": "SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments",
    "summary": "Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.",
    "url": "https://finnhub.io/api/news?id=759448bc8672bea87d54cfd23678b9036f8c6968e1c4ddee0158191ed9bcc855",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761068460,
      "headline": "SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments",
      "id": 137187979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.",
      "url": "https://finnhub.io/api/news?id=759448bc8672bea87d54cfd23678b9036f8c6968e1c4ddee0158191ed9bcc855"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=45278869ce83f3f6d2d457fe010ca9219d3c7facbbde2154f1fc96176c12a510",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761064380,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 137226340,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=45278869ce83f3f6d2d457fe010ca9219d3c7facbbde2154f1fc96176c12a510"
    }
  },
  {
    "ts": null,
    "headline": "Merck Kicks Off $3 Billion Expansion in Virginia",
    "summary": "New Elkton site to produce small molecule drugs and create 500 jobs.",
    "url": "https://finnhub.io/api/news?id=c2781837051d4ffba379d488e65794e86b42c074cb65fcba7af391b01fcf3ab7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761063713,
      "headline": "Merck Kicks Off $3 Billion Expansion in Virginia",
      "id": 137180648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "New Elkton site to produce small molecule drugs and create 500 jobs.",
      "url": "https://finnhub.io/api/news?id=c2781837051d4ffba379d488e65794e86b42c074cb65fcba7af391b01fcf3ab7"
    }
  },
  {
    "ts": null,
    "headline": "Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’",
    "summary": "We recently published 10 Trending Stocks This Week. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks this week. Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he recently bought Merck & Co Inc (NYSE:MRK). “I think at some point the market turns towards quality. […]",
    "url": "https://finnhub.io/api/news?id=c853e05ebb984584a077f094e24a4f69aedf1ff0e43e360256aa41db54605c9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761061825,
      "headline": "Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’",
      "id": 137180649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Trending Stocks This Week. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks this week. Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he recently bought Merck & Co Inc (NYSE:MRK). “I think at some point the market turns towards quality. […]",
      "url": "https://finnhub.io/api/news?id=c853e05ebb984584a077f094e24a4f69aedf1ff0e43e360256aa41db54605c9f"
    }
  },
  {
    "ts": null,
    "headline": "United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt",
    "summary": "The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he",
    "url": "https://finnhub.io/api/news?id=25b13d86b2cb421774c35a0a03bdf14ff9003d7ce01473fab5635abdf4118420",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761053400,
      "headline": "United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt",
      "id": 137177887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he",
      "url": "https://finnhub.io/api/news?id=25b13d86b2cb421774c35a0a03bdf14ff9003d7ce01473fab5635abdf4118420"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Growth Portfolio Drive Third-Quarter Results?",
    "summary": "Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.",
    "url": "https://finnhub.io/api/news?id=413d9b2081ab4cb54c5c4624de3ca641162dae59775f9933fd67df893d491a31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761051480,
      "headline": "Will BMY's Growth Portfolio Drive Third-Quarter Results?",
      "id": 137178115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.",
      "url": "https://finnhub.io/api/news?id=413d9b2081ab4cb54c5c4624de3ca641162dae59775f9933fd67df893d491a31"
    }
  },
  {
    "ts": null,
    "headline": "MSD initiates construction on $3bn Virginia drug manufacturing site",
    "summary": "The facility is part of the company’s $70bn US R&D and manufacturing expansion pledge.",
    "url": "https://finnhub.io/api/news?id=8f3c1dfc851a8245b729336a77330052508d42b087a2c63717d3fa476b98e168",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761049767,
      "headline": "MSD initiates construction on $3bn Virginia drug manufacturing site",
      "id": 137178117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The facility is part of the company’s $70bn US R&D and manufacturing expansion pledge.",
      "url": "https://finnhub.io/api/news?id=8f3c1dfc851a8245b729336a77330052508d42b087a2c63717d3fa476b98e168"
    }
  },
  {
    "ts": null,
    "headline": "The Play On Bristol-Myers Squibb",
    "summary": "The Play On Bristol-Myers Squibb",
    "url": "https://finnhub.io/api/news?id=e3b929cf488253a42fcf0278402ac90a1ec1fac6479996b4de42ff5f04886ce6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761046024,
      "headline": "The Play On Bristol-Myers Squibb",
      "id": 137178963,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e3b929cf488253a42fcf0278402ac90a1ec1fac6479996b4de42ff5f04886ce6"
    }
  },
  {
    "ts": null,
    "headline": "Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer",
    "summary": "CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the lum",
    "url": "https://finnhub.io/api/news?id=c02e4475d049c551ba2623057c6f337b8feef845231d79f1bd5a8f5ff4c62f49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761044400,
      "headline": "Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer",
      "id": 137178118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the lum",
      "url": "https://finnhub.io/api/news?id=c02e4475d049c551ba2623057c6f337b8feef845231d79f1bd5a8f5ff4c62f49"
    }
  },
  {
    "ts": null,
    "headline": "Iambic partners with Jazz; Merck breaks ground on $3B plant",
    "summary": "The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.",
    "url": "https://finnhub.io/api/news?id=711241990220e9dc9c45157cd4d9b23a2f7205f96ac4a7dcbeaf05768723d39a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761044100,
      "headline": "Iambic partners with Jazz; Merck breaks ground on $3B plant",
      "id": 137178852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.",
      "url": "https://finnhub.io/api/news?id=711241990220e9dc9c45157cd4d9b23a2f7205f96ac4a7dcbeaf05768723d39a"
    }
  },
  {
    "ts": null,
    "headline": "Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults",
    "summary": "RAHWAY, N.J., October 21, 2025--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults",
    "url": "https://finnhub.io/api/news?id=04bd9f03046503bad14e003f2a838e0c132fe182c4c7848eac94ab1f5f4467b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761043500,
      "headline": "Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults",
      "id": 137178120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 21, 2025--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults",
      "url": "https://finnhub.io/api/news?id=04bd9f03046503bad14e003f2a838e0c132fe182c4c7848eac94ab1f5f4467b4"
    }
  },
  {
    "ts": null,
    "headline": "SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology",
    "summary": "– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treat",
    "url": "https://finnhub.io/api/news?id=3322ddaad479a91a336ae839b4c6c97094ddbe125f06592740d1ec7541be9328",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761026400,
      "headline": "SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology",
      "id": 137174223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treat",
      "url": "https://finnhub.io/api/news?id=3322ddaad479a91a336ae839b4c6c97094ddbe125f06592740d1ec7541be9328"
    }
  }
]